MX2009013789A - Inhibidores de cisteina proteasa. - Google Patents
Inhibidores de cisteina proteasa.Info
- Publication number
- MX2009013789A MX2009013789A MX2009013789A MX2009013789A MX2009013789A MX 2009013789 A MX2009013789 A MX 2009013789A MX 2009013789 A MX2009013789 A MX 2009013789A MX 2009013789 A MX2009013789 A MX 2009013789A MX 2009013789 A MX2009013789 A MX 2009013789A
- Authority
- MX
- Mexico
- Prior art keywords
- protease inhibitors
- cysteine protease
- methyl
- methoxyvaline
- fluoroleucine
- Prior art date
Links
- 239000002852 cysteine proteinase inhibitor Substances 0.000 title 1
- UYFWXTAZASDCCA-BYPYZUCNSA-N (2s)-2-amino-4-fluoro-4-methylpentanoic acid Chemical compound CC(C)(F)C[C@H](N)C(O)=O UYFWXTAZASDCCA-BYPYZUCNSA-N 0.000 abstract 1
- WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 abstract 1
- RDBBJCUJCNMAAF-UHFFFAOYSA-N 2-azaniumyl-3-methoxy-3-methylbutanoate Chemical compound COC(C)(C)C(N)C(O)=O RDBBJCUJCNMAAF-UHFFFAOYSA-N 0.000 abstract 1
- 102000004171 Cathepsin K Human genes 0.000 abstract 1
- 108090000625 Cathepsin K Proteins 0.000 abstract 1
- 229930194542 Keto Natural products 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- 206010027452 Metastases to bone Diseases 0.000 abstract 1
- FYCWLJLGIAUCCL-DMTCNVIQSA-N O-methyl-L-threonine Chemical compound CO[C@H](C)[C@H](N)C(O)=O FYCWLJLGIAUCCL-DMTCNVIQSA-N 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- 125000000468 ketone group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
Compuestos de fórmula II: (ver figura) donde R2 es la cadena lateral de leunica, isoleucina, ciclohexilglicina, O-metiltreonina, 4-fluoroleucina o 3-metoxivalina; R3 es H, metilo o F; Rq es trifluorometilo y Rq' es H o Rq y Rq' define ceto; Q es una unidad p-(alquilo de 1 a 6 átomos de carbonosulfonil) fenilo o un 4-(alquilo de 1 a 6 átomos de carbonno) piperazin-1-il-tiazol-4-ilo opcionalmente sustituido con utilidad en el tratamiento de trastornos caracterizados por una expresión o activación inapropiadas de la catepsina K, como por ejemplo osteoporosis, osteartritis, artritis reumatoide o metástasis en hueso.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92943707P | 2007-06-27 | 2007-06-27 | |
| EP07123771 | 2007-12-20 | ||
| PCT/EP2008/058136 WO2009000877A1 (en) | 2007-06-27 | 2008-06-26 | Cysteine protease inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009013789A true MX2009013789A (es) | 2010-02-01 |
Family
ID=40020008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009013789A MX2009013789A (es) | 2007-06-27 | 2008-06-26 | Inhibidores de cisteina proteasa. |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US7893067B2 (es) |
| EP (1) | EP2167507B1 (es) |
| JP (1) | JP5501961B2 (es) |
| KR (1) | KR101552150B1 (es) |
| CN (1) | CN101687880B (es) |
| AR (1) | AR067363A1 (es) |
| AU (1) | AU2008267166B2 (es) |
| BR (1) | BRPI0813763A2 (es) |
| CA (1) | CA2690344C (es) |
| DK (1) | DK2167507T3 (es) |
| EA (1) | EA017395B1 (es) |
| ES (1) | ES2573229T3 (es) |
| MX (1) | MX2009013789A (es) |
| MY (1) | MY149191A (es) |
| PL (1) | PL2167507T3 (es) |
| TW (1) | TWI419893B (es) |
| WO (1) | WO2009000877A1 (es) |
| ZA (1) | ZA200908771B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7893067B2 (en) | 2007-06-27 | 2011-02-22 | Medivir Ab | Cysteine protease inhibitors |
| GB0817424D0 (en) | 2008-09-24 | 2008-10-29 | Medivir Ab | Protease inhibitors |
| WO2010137944A1 (en) * | 2009-05-27 | 2010-12-02 | N.V. Nutricia | Treatment of hypercalcaemia |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR013079A1 (es) | 1997-05-06 | 2000-12-13 | Smithkline Beecham Corp | Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios |
| GB0003111D0 (en) | 2000-02-10 | 2000-03-29 | Novartis Ag | Organic compounds |
| IL155958A0 (en) | 2000-11-17 | 2003-12-23 | Medivir Ab | Cysteine protease inhibitors |
| AU2002219397B2 (en) | 2001-01-17 | 2008-02-14 | Grünenthal GmbH | Inhibitors of cruzipain and other cysteine proteases |
| WO2005056529A1 (en) | 2003-12-12 | 2005-06-23 | Merck Frosst Canada Ltd. | Cathepsin cysteine protease inhibitors |
| WO2005065578A2 (en) | 2004-01-06 | 2005-07-21 | Nicast Ltd. | Vascular prosthesis with anastomotic member |
| DE602005019971D1 (de) | 2004-01-08 | 2010-04-29 | Medivir Ab | Inhibitoren von cysteinprotease |
| CA2552726A1 (en) | 2004-01-08 | 2005-07-21 | Merck Frosst Canada Ltd. | Cathepsin cysteine protease inhibitors |
| GB0513839D0 (en) | 2005-07-07 | 2005-08-10 | Medivir Ab | Cysteine protease inhibitors |
| GB0614052D0 (en) | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| US7893067B2 (en) * | 2007-06-27 | 2011-02-22 | Medivir Ab | Cysteine protease inhibitors |
| GB0804702D0 (en) * | 2008-03-13 | 2008-04-16 | Amura Therapeutics Ltd | Compounds |
-
2008
- 2008-06-25 US US12/145,987 patent/US7893067B2/en not_active Expired - Fee Related
- 2008-06-26 JP JP2010513917A patent/JP5501961B2/ja not_active Expired - Fee Related
- 2008-06-26 MX MX2009013789A patent/MX2009013789A/es active IP Right Grant
- 2008-06-26 MY MYPI20095560A patent/MY149191A/en unknown
- 2008-06-26 CN CN200880021888XA patent/CN101687880B/zh not_active Expired - Fee Related
- 2008-06-26 WO PCT/EP2008/058136 patent/WO2009000877A1/en not_active Ceased
- 2008-06-26 EA EA201070062A patent/EA017395B1/ru not_active IP Right Cessation
- 2008-06-26 DK DK08774321.7T patent/DK2167507T3/en active
- 2008-06-26 EP EP08774321.7A patent/EP2167507B1/en active Active
- 2008-06-26 AU AU2008267166A patent/AU2008267166B2/en not_active Ceased
- 2008-06-26 KR KR1020107001823A patent/KR101552150B1/ko not_active Expired - Fee Related
- 2008-06-26 PL PL08774321.7T patent/PL2167507T3/pl unknown
- 2008-06-26 BR BRPI0813763-3A2A patent/BRPI0813763A2/pt not_active Application Discontinuation
- 2008-06-26 CA CA2690344A patent/CA2690344C/en not_active Expired - Fee Related
- 2008-06-26 ES ES08774321.7T patent/ES2573229T3/es active Active
- 2008-06-27 TW TW097124370A patent/TWI419893B/zh not_active IP Right Cessation
- 2008-06-27 AR ARP080102813A patent/AR067363A1/es not_active Application Discontinuation
-
2009
- 2009-12-09 ZA ZA2009/08771A patent/ZA200908771B/en unknown
-
2011
- 2011-01-07 US US12/986,830 patent/US8198283B2/en not_active Expired - Fee Related
-
2012
- 2012-05-10 US US13/468,787 patent/US8466158B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| TW200911818A (en) | 2009-03-16 |
| MY149191A (en) | 2013-07-31 |
| JP2010531336A (ja) | 2010-09-24 |
| KR101552150B1 (ko) | 2015-09-10 |
| US20090023748A1 (en) | 2009-01-22 |
| DK2167507T3 (en) | 2016-06-13 |
| EP2167507B1 (en) | 2016-03-02 |
| AU2008267166A1 (en) | 2008-12-31 |
| KR20100040879A (ko) | 2010-04-21 |
| EA017395B1 (ru) | 2012-12-28 |
| CA2690344A1 (en) | 2008-12-31 |
| US7893067B2 (en) | 2011-02-22 |
| TWI419893B (zh) | 2013-12-21 |
| WO2009000877A1 (en) | 2008-12-31 |
| EP2167507A1 (en) | 2010-03-31 |
| EA201070062A1 (ru) | 2010-08-30 |
| US20110105524A1 (en) | 2011-05-05 |
| ES2573229T3 (es) | 2016-06-06 |
| BRPI0813763A2 (pt) | 2014-12-30 |
| JP5501961B2 (ja) | 2014-05-28 |
| CA2690344C (en) | 2015-06-02 |
| US8198283B2 (en) | 2012-06-12 |
| PL2167507T3 (pl) | 2016-09-30 |
| US20120220602A1 (en) | 2012-08-30 |
| AR067363A1 (es) | 2009-10-07 |
| HK1140480A1 (en) | 2010-10-15 |
| US8466158B2 (en) | 2013-06-18 |
| ZA200908771B (en) | 2011-04-28 |
| AU2008267166B2 (en) | 2011-04-21 |
| CN101687880A (zh) | 2010-03-31 |
| CN101687880B (zh) | 2012-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2000011I1 (hu) | A 2,4-pirimidin-diamin vegyületek elõgyógyszerei és alkalmazásuk | |
| MX285770B (es) | Polimeros obtenidos por el uso de compuestos azufrados en forma de agentes de transferencia para la polimerizacion controlada de radicales del acido acrilico y sus aplicaciones. | |
| MXPA05011643A (es) | 5,7-diaminopirazolo[4,3-d]pirimidinas en el tratamiento de hipertension. | |
| WO2008109697A3 (en) | Ppar active compounds | |
| MX2007011023A (es) | 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3. | |
| WO2009016253A3 (en) | Cyanomethyl substituted n-acyl tryptamines | |
| WO2007109456A3 (en) | Substituted biphenyl isoxazole sulfonamides as dual angiotensin endothelin receptor antagonists | |
| UA101911C2 (en) | Fungicidal composition | |
| MX2010006143A (es) | Azolilmetiloxiranos, su uso y agentes que lo contienen. | |
| TW200732341A (en) | Chemical compounds | |
| JO2860B1 (en) | Phenylendazolyl compounds | |
| MX337083B (es) | Pesticidas y usos de los mismos. | |
| MX2009012421A (es) | Inhibicion de metastasis de tumor por anticuerpos anti neuropilina 2. | |
| GEP20125404B (en) | Tricyclic compounds and their use as glucocorticoid receptor modulators | |
| SG178999A1 (en) | Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| TW200604158A (en) | New sulphur compounds: use as transfer agents for controlled radical polymerisation of acrylic acid, polymers obtained and applications thereof | |
| EA200970098A1 (ru) | Понизитель водоотдачи для буровых растворов на масляной основе | |
| UA102289C2 (ru) | Гербициды, полученные из циклопентадиона | |
| CL2007002389A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de obesidad, hirsutismo, hipertricosis y verrugas viricas. | |
| MY142105A (en) | Leukotriene biosynthesis inhibitors | |
| TW200630367A (en) | Substituted adenines and the uses thereof | |
| MX2009013789A (es) | Inhibidores de cisteina proteasa. | |
| MX2008007808A (es) | Analogos de rifamicina y usos de ellos. | |
| NZ703381A (en) | Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine | |
| WO2007019191A3 (en) | Thiazolopyrimidine kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |